SEQUENOM's first laboratory developed cystic fibrosis test launched

SEQUENOM, Inc. (Nasdaq: SQNM) today announced that the company's first laboratory developed test, the SensiGene(TM) Cystic Fibrosis (CF) Carrier Screening test, has been launched. This test is available exclusively through the Sequenom Center for Molecular Medicine, a next-generation CLIA (Clinical Laboratory Improvement Amendments, 1988) molecular diagnostic laboratory and a wholly-owned subsidiary of Sequenom, Inc.

The SensiGene CF Carrier Screening Test

  • This innovative test screens for 103 mutations and five variants, including the 23 mutations recommended by the American College of Medical Genetics (ACMG). This test has been shown to identify each of the 103 mutations and five variants through genomic DNA and DNA control testing.
  • The test offers superior detection rates and broader ethnic coverage when compared to the standard ACMG 23 recommended mutations panel. Because of the increased difficulty in assigning a single ethnicity to an individual, expanded CF panels can provide increased sensitivity for CF carrier screening for many individuals. Having a more comprehensive mutation panel is important as 1 in 17 CF carriers may be missed using a standard ACMG 23 CF carrier screening panel.
  • The test employs Sequenom's proprietary MassARRAY(R) system, which allows direct and label-free analysis of nucleic acids.

"As the world's population becomes more of a melting pot in terms of ethnicity and diversity, a more comprehensive test like the SensiGene Cystic Fibrosis Carrier Screening test is essential in the world of genetic testing," said Lee P. Shulman MD, Professor in Obstetrics and Gynecology and Chief of the Division of Reproductive Medicine at the Feinberg School of Medicine at Northwestern University.

Carrier screening tests help identify individuals who may have an increased risk of having a baby with certain genetic conditions. Healthy individuals with no family history of the condition and that already have healthy children, may be carriers of a genetic condition; for example, cystic fibrosis. Approximately 1 in 30 Americans - more than 10 million people - are carriers of a cystic fibrosis gene mutation, making it one of the most common genetic disorders in the United States. Children have cystic fibrosis when they have two mutations in the gene that cause CF - inheriting one mutation from the mother and the other from the father. According to the American College of Obstetricians and Gynecologists (ACOG) and the ACMG, cystic fibrosis carrier screening should be offered to all Caucasian couples who are expecting a baby or are considering pregnancy, and further, should be made available to all patients regardless of ethnicity. About 1.1 million cystic fibrosis carrier screening tests are performed each year in the U.S. With an average reimbursement rate of $200-$400 per test; the U.S. market is estimated to be in excess of $300 million per year.

"The commercial launch of this test is an important milestone for us as it marks the first laboratory developed test launched by our lab, the Sequenom Center for Molecular Medicine," stated Harry Stylli, PhD, Sequenom's president and chief executive officer. "This screening tool offers an outstanding testing option for patients and their care providers. We are developing and plan to offer a menu of superior women's health related molecular tests, including proprietary, cell free fetal nucleic acid based tests such as fetal sex determination, fetal RHD genotyping, trisomy 21 and others."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Prime editing offers promising path to permanent treatment for cystic fibrosis